....and I thought the Kohler report sent the stock higher nicely....
This was, you will recall, the same type of study that saw Striate quickly approved by both the TGA and FDA. Long overdue, but coming at last. Remplir on the Aussie mkt already, hopefully US and EU to quickly follow in 2024. This product on the Aussie prosthesis list for near $1,400 remember. This could potentially bring even more eventual revenues than Striate with Bio Horizons.......
OCC Price at posting:
42.0¢ Sentiment: Buy Disclosure: Held
